CRISPR Therapeutics
CRSP
$55.67
Share price
-2.26%
Change (1 day)
-15.59%
Change (1 year)
P/S ratio for CRISPR Therapeutics (CRSP)
P/S ratio as of May 2024 (TTM): 13.1
According to CRISPR Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 13.0728. At the end of 2023 the company had a P/S ratio of 13.4.
P/S ratio history for CRISPR Therapeutics from 2016 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 13.4 | -99.82% |
| 2022 | > 1000 | 114832.63% |
| 2021 | 6.35 | -99.97% |
| 2020 | > 1000 | 156961.57% |
| 2019 | 12.8 | -97.3% |
| 2018 | 474 | 1956.93% |
| 2017 | 23.1 | -85.24% |
| 2016 | 156 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | N/A | N/A | 🇺🇸 USA |